



TriMark Publications

June 2012
Volume: TMRCAT12-0601

CATHETER MARKETS

(SAMPLE COPY, NOT FOR RESALE)

Trends, Industry Participants, Product Overviews and Market Drivers

TABLE OF CONTENTS

1. Introduction	16
1.1 Scope of this Report	16
1.2 Methodology	16
1.3 Executive Summary	17
2. Catheter Uses and Types	19
2.1 Scope of this Chapter	19
2.2 Catheter Uses	19
2.3 Types of Catheters	20
2.3.1 Cardiovascular Catheters	20
2.3.1.1 Cardiac Catheterization Procedures	21
2.3.1.2 Indications for Cardiac Catheterization	22
2.3.2 Percutaneous Coronary Intervention (PCI)	22
2.3.3 Athrectomy	22
2.3.4 Ventricular Angiogram	23
2.3.5 Coronary Flow Reserve Measurements	24
2.3.6 Intravascular Ultrasound Imaging	24
2.3.7 Pericardiocentesis	25
2.3.8 Heart Biopsy Catheters	25
2.3.9 Atrial Fibrillation Catheters	25
2.3.10 Ablation Electrophysiology Catheters	26
2.3.10.1 New Cardiac Ablation Technology Trends	26
2.3.10.2 Next Generation Atrial Fibrillation Ablation Catheters	27
2.4 Urological Applications of Catheters	28
2.4.1 Condom Catheters	28
2.4.2 Indwelling Urethral Catheters	29
2.4.3 Intermittent Catheters	29
2.4.4 Dialysis Catheters	30
2.4.4.1 Advances in Urinary Catheter Technology	30
2.4.4.2 Biocompatibility	30
2.4.4.3 Biofilms and Encrustation	31
2.4.4.4 Issues in Intermittent Self-Catheterization	31
2.4.4.5 Coatings for Urinary Catheters	31
2.5 Neurovascular Applications of Catheters	31
2.6 Venous Access Applications of Catheters	32
2.6.1 Central Venous Catheters (CVC)	32
2.6.2 Short Peripheral Inserted Catheters (PIC)	33
2.6.3 Midline Catheters (MC)	33
2.6.4 Peripherally Inserted Central Catheter (PICC)	33
2.6.5 Pulmonary Artery Catheters (PAC)	34
2.6.6 Tunneled Central Catheters	34
2.6.7 Implanted Ports for Central Catheters	34
2.7 Oximetric Catheter	35
2.8 Thermodilution Catheters	35
2.9 Suction Catheters	35
2.10 Wound Drainage Catheters	36
2.11 Umbilical Catheters	36
2.12 Catheter Coating	36
2.13 Comparison of Three Common Catheter Materials	36
2.13.1 Silicones	37
2.13.2 Polyvinyl Chloride	37
2.13.3 Latex Rubber	37
2.14 Comparison of Silicone, PVC and Latex	37
2.15 The Making of Catheters	38
2.15.1 History	38

2.15.2 Raw Materials and Design	39
3. Disease Conditions that Fuel the Growth of Catheter Market	40
3.1 Scope of this Chapter	40
3.1 Cardiovascular Diseases	40
3.1.1 Mortality from Heart Disease and Stroke in Selected OECD Countries	45
3.1.2 Market for Cardiovascular Devices	48
3.1.3 Market Leaders in Cardiovascular Devices	49
3.2 Catheters and Ports in Cancer Treatment	49
3.2.1 Cancer in the U.S.	50
3.2.2 Mortality from Cancer in OECD Countries	53
3.2.3 Global Oncology Market	57
3.3 Renal Failure	57
3.3.2 Renal Failure in OECD Countries	58
3.3.3 Global Dialysis Market	60
3.3.4 Number of Dialysis Patients Globally	60
3.3.5 Number of U.S. Dialysis Patients	61
3.3.6 U.S. Dialysis Market	62
3.3.7 U.S. Dialysis Procedures by Segment	62
4. Trends in Overall Medical Device Industry	64
4.1 Scope of this Chapter	64
4.1.1 Global Medical Device Market	64
4.1.2 Market for Medical Devices in Americas	65
4.1.3 Medical Device Market in Western Europe	65
4.1.4 Medical Device Market in Central and Eastern Europe	66
4.1.5 Medical Device Market in Asia/Pacific	67
4.1.6 Medical Device Market in Middle East/Africa	67
4.1.7 Medical Device Market in China and India	68
5. Catheter Market: Overview	69
5.1 Scope of this Chapter	69
5.2 Segmentation of Catheter market	69
5.2.1 Global Market for Catheters	70
5.2.2 Market for Catheters in Americas	71
5.2.3 Catheter Market in Europe, Middle East, Russia and Africa, 2011-2018	72
5.2.4 Asia/Pacific Market for Catheters	72
5.2.5 Catheter Market in Japan	73
5.2.6 Global Catheter Market by Region	74
5.2.7 Global Catheter Market by Disease Segment	74
5.3 Market for Cardiovascular Catheters	75
5.3.1 Global Market for Diagnostic Catheters by Type	76
5.3.2 Global Market for Balloon Catheters	77
5.3.3 The Rise of Balloon Catheters in the U.S.	78
5.3.4 Fast Changing DEBs Market	78
5.3.5 Global Market for Electrophysiology Ablation Catheters	79
5.3.6 North American Market for Electrophysiology Ablation Catheters	80
5.3.7 European Market for Electrophysiology Ablation Catheters	80
5.3.8 Asia/Pacific Market for Electrophysiology Ablation Catheters	81
5.3.9 Single-Use Cardiac Catheter market	82
5.3.9.1 Global Market for Single-Use Catheters in Conventional Diagnostics	82
5.3.9.2 Global Market for Single-Use Catheters Used in Standard Ablation	83
5.3.9.3 Global Market for Single-Use Catheters Used in Advanced Diagnostics	84
5.3.9.4 Global Market for SUD Catheters Used in Irrigated Ablation	84
5.4 Global Market for Urological Catheters	85
5.4.1 FDA-Approved Urological Catheters	86
5.4.2 U.S. Urology Devices Market	87
5.4.3 U.S. Intermittent Catheters Market	87
5.4.4 Market Leaders in Intermittent Catheters	88

5.4.5	Market Leaders in Foley Catheters	89
5.4.6	U.S. Market for Urinary Incontinence Products by Type	89
5.4.7	U.S. Urinary Incontinence Market by Segment	90
5.4.8	Market Leaders in Male External Catheters	90
5.5	Global Market for Central Venous Catheters	91
5.5.1	Global Central Venous Catheter (CVC) Market by Region	91
5.5.2	Market Leaders in Central Venous Catheter Market	92
5.5.3	Market Leaders in Implantable Catheter Ports	92
6.	Global Market for Tissue Ablation Devices	94
6.1	Scope of this Chapter	94
6.1.1	Share of the Ablation Technologies by Clinical Specialty	94
6.1.2	Global Ablation Devices Market by Type	95
6.1.3	Electrical and Electrocautery Devices	96
6.1.4	Radiation Devices	97
6.1.5	Light-Based Ablation Devices	97
6.1.6	Radiofrequency (RF) Energy	98
6.1.7	Market Leaders in RF Ablation Devices	99
6.1.8	Ultrasound Energy	99
6.1.9	Cryotherapy	100
6.1.10	Thermal Ablation	101
6.1.11	Microwave Hyperthermia	101
6.1.12	Hydromechanical Ablation	102
6.2	U.S. Market for Tissue Ablation Devices	103
6.2.1	Cryoablation in the U.S.	103
6.2.2	Hydromechanical Ablation Therapy in the U.S.	104
6.2.3	Ultrasound Tissue Ablation in the U.S.	105
6.2.4	Radiofrequency Ablation Therapy in the U.S.	105
6.2.5	Market for Tissue Ablation Devices in Asia/Pacific	106
6.2.5.1	Market for Tissue Ablation Devices in Japan	107
6.2.5.2	Chinese Market for Tissue Ablation Devices	107
6.2.5.3	Australian Market for Tissue Ablation Devices	108
6.2.5.4	Market for Tissue Ablation in India	109
6.3	Share of the Ablation Technologies by Clinical Specialty	109
6.3.1	Cancer Ablation Market by Type of Cancer	110
6.3.2	Global Ablation Technologies Market by Modality	111
7.	Free Standing Diagnostic Cath Lab Market in the U.S.	112
7.1	Reimbursement Trends	112
7.2	Joint Venture Options	113
7.3	Payer Mix and Volume	113
7.4	Overhead Expenses	114
7.5	Space Requirements and Costs	114
7.6	Personnel Staffing	115
7.7	Credentialing Requirements and Responsible Oversight	116
7.8	Considering Structural Alternatives	116
8.	Coding and Payment Information for Catheters, 2012	119
8.1	Medicare Coverage Policy	119
8.2	Private Insurance Coverage	119
8.3	Documentation	119
8.4	Codes and Payments for Hospitals for Procedures Performed in Outpatient Setting	119
8.4.1	Codes and Payments for Inpatient Procedures	120
8.4.2	Codes and Payments for ASC Outpatient Procedures	120
8.5	Physician Payments	120
8.5.1	Physician Payment for Procedures Performed at a Facility	120
8.5.2	Physician Payment Performed in a Non-Facility Setting	120
8.6	Supplies	120
8.7	Appeals	121

- 9. Selected Company Profiles 125
 - 9.1 Abbott Laboratories 125
 - 9.1.1 Agiltrac 018 Peripheral Dilatation Catheter 125
 - 9.1.2 Fox Plus PTA Catheter 125
 - 9.1.3 Fox sv PTA Catheter 126
 - 9.1.4 FoxCross 035 PTA Catheter 126
 - 9.1.5 Veripath Peripheral Guiding Catheter 126
 - 9.1.6 Powersail Coronary Dilatation Catheter 126
 - 9.1.7 Rx Viatrac 14 Plus Peripheral Dilatation Catheter 127
 - 9.1.8 Trek & Mini Trek Coronary Dilatation Catheter 127
 - 9.2 Abiomed, Inc. 127
 - 9.2.1 Impella 2.5 128
 - 9.2.2 Impella 5.0 128
 - 9.2.3 Impella LD 129
 - 9.3 AngioDynamics, Inc. 129
 - 9.3.1 Selected Products from AngioDynamics 130
 - 9.3.1.1 UniFuse Infusion Catheter 130
 - 9.3.1.2 NeoStar™ Triple Lumen Catheter 130
 - 9.3.1.3 Soft-Vu 4 French High Flow 131
 - 9.3.1.4 Omni Flush Angiographic Catheter 131
 - 9.3.1.5 SOS Omni Selective Catheter 131
 - 9.3.1.6 Mariner™ Hydrophilic Coated Angiographic Catheter 132
 - 9.3.1.7 Total Abscession Drainage Catheter 132
 - 9.3.1.8 Accu-Vu Sizing Catheter 132
 - 9.3.1.9 AngiOptic Flush and Selective Catheters 133
 - 9.3.1.10 Profiler Balloon Dilation Catheter 133
 - 9.3.1.11 WorkHorse II PTA Balloon Catheter 134
 - 9.3.1.12 DuraMax Chronic HemoDialysis Catheter 134
 - 9.3.1.13 Dura-Flow Chronic Hemodialysis Catheter 134
 - 9.3.1.14 SCHON XL Acute Hemodialysis Catheter 135
 - 9.3.1.15 LifeJet VP VascPak 135
 - 9.3.1.16 EVENMORE Chronic Dialysis Catheter 135
 - 9.3.1.17 Schon Chronic Hemodialysis Catheter 136
 - 9.3.1.18 EMBOSAFE Valved, Splittable Sheath Dialtor 136
 - 9.4 Astra Tech AB 137
 - 9.4.1 LoFric Primo 137
 - 9.4.2 LoFric 137
 - 9.4.3 LoFric Hydro-Kit 137
 - 9.4.4 LoFric Dila Cath 137
 - 9.5 AtriCure, Inc. 138
 - 9.6 B. Braun Melsungen AG 138
 - 9.6.1 B. Braun's Intermittent Catheters 138
 - 9.6.1.1 Actreen® Lite Mini (Female Self Intermittent Catheter) 139
 - 9.6.1.2 Actreen® Lite Cath Tiemann Male 139
 - 9.6.1.3 Actreen® Lite Cath Nelaton Male 139
 - 9.6.1.4 Actreen® Lite Cath Nelaton Female 140
 - 9.6.1.5 Actreen® SafeCath Tiemann Male 140
 - 9.6.1.6 Actreen® SafeCath Nelaton Female 141
 - 9.6.1.7 Actreen® Glyc Cath Tiemann Male 141
 - 9.6.1.8 Actreen® Glyc Cath Nelaton Male 141
 - 9.6.1.9 Actreen® Glyc Cath Nelaton Female 142
 - 9.6.2 Vesical Instillation Catheters 142
 - 9.6.2.1 Actreen® Glyc Luer Lock Tiemann Male 142
 - 9.6.2.2 Actreen® Glyc Luer Lock Nelaton Male 143
 - 9.6.2.3 Actreen® Glyc Luer Lock Nelaton Female 143
 - 9.6.3 Male External Catheters 143

- 9.6.3.1 Urimed® Vision Standard 143
- 9.6.3.2 Urimed® Vision Short 144
- 9.6.4 Urological Catheters 144
 - 9.6.4.1 Transurethral Balloon Catheter, Nelaton Tip 144
 - 9.6.4.2 Transurethral Balloon Catheter, Tiemann Tip 145
 - 9.6.4.3 Nelaton Catheter 145
 - 9.6.4.4 Tiemann Catheter 145
 - 9.6.4.5 Tiemann-Katheter with lubricant 146
- 9.6.5 Female Catheter 146
 - 9.6.5.1 Cystofix® Basic Set (acute and medium term care) 146
 - 9.6.5.2 Cystofix® Replacement Set 147
 - 9.6.5.3 Cystofix® Dilation Replacement Set with Balloon Catheter 147
 - 9.6.5.4 Cystofix® Basic Set with Balloon Catheter (long term care) 147
 - 9.6.5.5 Cystofix® TUR 148
 - 9.6.5.6 Cystofix® Paed Basic Set 148
 - 9.6.5.7 Cystofix® Paediatrics and Neonatology Replacement Set 148
 - 9.6.5.8 Nephrofix® 149
 - 9.6.5.9 Nephrofix® Certo 149
- 9.7 Becton, Dickinson & Co. 149
- 9.8 Boston Scientific 152
 - 9.8.1 Boston's Advanced Mapping Catheters 152
 - 9.8.1.1 AFocus™ Steerable Diagnostic Catheters 152
 - 9.8.1.2 Constellation® Full Contact Mapping Catheter 153
 - 9.8.1.3 Inquiry® H-Curve™ Steerable Diagnostic Catheters 153
 - 9.8.1.4 Luma-Cath™ Fixed & Steerable Curve Diagnostic Catheters 154
 - 9.8.1.5 Ten-Ten™ Duodecapolar Diagnostic Catheters 154
 - 9.8.2 Boston's Diagnostic Catheters 154
 - 9.8.2.1 Blazer® Dx-20 Bidirectional Duodecapolar Diagnostic Catheter 154
 - 9.8.2.2 Explorer 360™ and 360 Jr™ Diagnostic Catheters 155
 - 9.8.2.3 Inquiry® Fixed Curve Diagnostic Catheters 155
 - 9.8.2.4 Inquiry® HIS Diagnostic Catheters 155
 - 9.8.2.5 Inquiry® Steerable Diagnostic Catheters 156
 - 9.8.2.6 Polaris Dx™ Steerable Diagnostic Catheter 156
 - 9.8.2.7 Polaris X™ Steerable Diagnostic Catheters 156
 - 9.8.2.8 SteeroCath-Dx™ Bi-Directional Steerable Diagnostic Catheters 157
 - 9.8.3 Boston's Therapeutic Catheters 157
 - 9.8.3.1 Blazer Prime® HTD and Blazer Prime® XP Temperature Catheters 157
 - 9.8.3.2 Blazer® II XP Temperature Ablation Catheter 158
 - 9.8.3.3 Blazer® Temperature Ablation Catheters 158
 - 9.8.3.4 Chilli II® Cooled Ablation Catheters 159
 - 9.8.4 Boston's Catheters in Gastroenterology 160
 - 9.8.4.1 Gold Probe™ Electrohemostasis Catheter 160
 - 9.8.4.2 Injection Gold Probe™ Hemostasis Catheter 160
 - 9.8.5 Angiographic Catheter in Interventional Radiology 161
 - 9.8.5.1 iCross™ Coronary Imaging Catheter 161
 - 9.8.6 Selected Balloon Catheter in Interventional Radiology 161
 - 9.8.6.1 Berenstein Large Lumen Occlusion Balloon Catheter 161
 - 9.8.6.2 Charger™ 0.035" Balloon Dilatation Catheter 162
 - 9.8.6.3 Coyote™ Balloon Dilatation Catheter 162
 - 9.8.6.4 Sterling® ES Balloon Dilatation Catheters 163
 - 9.8.6.5 Sterling® SL Balloon Dilatation Catheter 163
 - 9.8.6.6 Sterling™ Monorail® Balloon Dilatation Catheters 164
 - 9.8.7 Urology Balloon Catheters 164
 - 9.8.7.1 NephroMax™ High Pressure Nephrostomy Balloon Catheter 164
 - 9.8.7.2 UroMax Ultra™ High Pressure Balloon Catheter 165
- 9.9 Coloplast A/S 165

- 9.9.1 SpeediCath Control 165
- 9.9.2 SpeediCath Compact 166
- 9.9.3 SpeediBag Compact 166
- 9.9.4 SpeediCath Complete 166
- 9.9.5 SpeediCath Compact Male 167
- 9.9.6 Conveen Optima 167
- 9.9.7 Conveen Optima and Conveen Active 167
- 9.10 Cook Medical, Inc. 168
 - 9.10.1 Anesthetic Injection Catheter 168
 - 9.10.2 Angled Tip Ureteral Catheter 168
 - 9.10.3 Bush DL™ Ureteral Illuminating Catheter Set 168
 - 9.10.4 Bush SL™ Ureteral Illuminating Catheter Set 169
 - 9.10.5 Cohen Deflecting Wire Guide Catheter 169
 - 9.10.6 Cone Tip Ureteral Catheter 169
 - 9.10.7 Echotip® Open-End Ureteral Catheter 169
 - 9.10.8 Flexi-Tip® Ureteral Catheter 169
 - 9.10.9 Kumpe Access Catheter 170
 - 9.10.10 Laser Ureteral Catheter 170
 - 9.10.11 Madduri Ureteral Stone Pushing Catheter 170
 - 9.10.12 Malleable Tip Open-End Ureteral Catheter 170
 - 9.10.13 Open-End Flexi-Tip® Ureteral Catheter 171
 - 9.10.14 Open-End Tapered Tip Ureteral Catheter 171
 - 9.10.15 Open-End Ureteral Catheter Sof-flex® 171
 - 9.10.16 Pediatric Ureteral catheter 171
 - 9.10.17 Pigtail Ureteral Catheter Sof-Flex® AQ® 171
 - 9.10.18 Pigtail Ureteral Catheter Set 172
 - 9.10.19 Renal Access Cobra Catheter 172
 - 9.10.20 Round Tip Ureteral Catheter 172
 - 9.10.21 Rutner Universal Wedge Catheter 172
 - 9.10.22 Schoborg Angled Tip Laser Catheter 173
 - 9.10.23 Spiral Tip Ureteral Access Catheter 173
- 9.11 Edwards Lifesciences Corporation 173
 - 9.11.1 Edward's Central Venous Catheters 174
 - 9.11.1.1 Vantex Antimicrobial Central Venous Catheters 174
 - 9.11.1.2 IntroFlex Introducers 174
 - 9.11.1.3 Multimed Catheters 174
 - 9.11.1.4 AVA 3Xi Device 175
 - 9.11.1.5 AVA High-Flow Device 175
 - 9.11.1.6 PreSep Central Venous Oximetry Catheter (ScvO2) 175
 - 9.11.1.7 PediaSat Oximetry Catheter (ScvO2) 176
 - 9.11.2 Balloon Atriostomy Catheters 176
- 9.12 Hollister, Inc. 177
 - 9.12.1 Hollister's Continence Care Products 177
 - 9.12.1.2 Apogee Intermittent Catheters 177
 - 9.12.1.3 Apogee Closed System 177
 - 9.12.1.4 Advance Plus Touch Free Intermittent Catheter 177
 - 9.12.1.5 InView Male External Catheters 178
 - 9.12.1.6 Extended Wear Male External Catheter 178
 - 9.12.1.7 Everyday Male External Catheter 178
 - 9.13 Medcomp 179
 - 9.13.1 Long Term Hemodialysis Catheters 179
 - 9.13.1.1 Split Cath 179
 - 9.13.1.2 Split Stream 179
 - 9.13.1.3 Eschelon 180
 - 9.13.1.4 Bio-Flex Tesio Cath 180
 - 9.13.1.5 Titan HD 180

- 9.13.1.6 Hemo Flow 180
- 9.13.1.7 Hemo-Cath LT 181
- 9.14 Prolinx GmbH 181
- 9.14.1 ProCath® Silicone-Elastomer Coated Foley Catheters 181
- 9.14.2 ProCath® Silicone Foley Catheter 182
- 9.14.3 ProCath® Solo Intermittent Catheter 182
- 9.14.4 ProCath® Plus Intermittent Catheter 183
- 9.14.5 ProCath® Kit Plus Intermittent Catheter 183
- 9.14.6 ProCath® Closed Urine Drainage Systems PL 2000 184
- 9.14.7 ProCath® Bed Drainage Bag PL 2000E 184
- 9.14.8 ProCath® Leg bag PL 500 184
- 9.14.9 ProCath® Closed Urine Drainage Systems PL 1000 185
- 9.14.10 Catheterization Kit 185
- 9.15 Rochester Medical Corporation 186
- 9.15.1 Male External Catheters 186
- 9.15.2 Intermittent Catheters 186
- 9.15.3 Silicone Foley Catheters 186
- 9.15.4 Anti-Infection Foley Catheters 187
- 9.15.5 Urethral Inserts 187

APPENDIX

- Appendix 1: Guidelines for Indwelling Catheterization in Adults 188
- Appendix 1.1: Transurethral or Suprapubic Catheterisation 188
- Appendix 1.2: Short-Term and Long-Term Catheterization 188
- Appendix 1.3: Closed Drainage System 188
- Appendix 1.4: Alternatives to Placing an Indwelling Catheter 189
- Appendix 1.5: Indications for Urethral Catheterization 189
- Appendix 1.6: Contraindications for Urethral Catheterization 189
- Appendix 1.7: Short-Term vs. Long-Term Catheterization 189
- Appendix 1.8: Indications for Suprapubic Catheterization 190
- Appendix 1.9: Contraindications for Suprapubic Catheterization 190
- Appendix 1.10: Advantages of Suprapubic Catheterization 190
- Appendix 1.11: Limitations of Suprapubic Catheters 190
- Appendix 1.12: Equipment and Products for Catheterization 191
- Appendix 1.12.1: Types of Catheters 191
- Appendix 1.12.2: Catheter Material 193
- Appendix 1.12.3: Catheter Diameter 194
- Appendix 1.12.4: Catheter Length 194
- Appendix 1.12.5: Catheter Tip Design 194
- Appendix 1.12.6: Drainage Bags 196
- Appendix 2: Minimally Invasive Medical Technologies 200
- Appendix 2.1: Market Share for Minimally-Invasive Medical Technologies 200
- Appendix 2.2: Market Size and Growth 201
- Appendix 2.3: Patient Demand for Minimally-Invasive Procedures 205
- Appendix 2.4: Advances in Electrosurgical Tools 206
- Appendix 2.5: Advances in Robotics 207
- Appendix 2.6: Clinical Opportunities for Minimally-Invasive Medical Technologies 207
- Appendix 3: High-Impact Emerging Medical Technologies 209
- Appendix 3.1: Emerging Cardiology/Vascular Market 209
- Appendix 3.1.1: Diagnostic Technologies 210
- Appendix 3.1.1.1: Implantable Cardiac Pressure Monitors 210
- Appendix 3.1.1.2: Ultra-Wideband Radar 211
- Appendix 3.1.1.3: Bioimpedance Plethsmograph 212
- Appendix 3.1.2: Therapeutic Technologies 214
- Appendix 3.1.2.3: MRI-Compatible Pacemakers 216

- Appendix 3.1.2.4: Ultrasound-Enhanced Thrombolytics 217
- Appendix 3.1.2.5: Image-Guided Intracardiac Surgery (IGIS) 218
- Appendix 3.1.2.6: Autologous Cell Therapy 219
- Appendix 3.1.2.7: External Cardiac Basal Annuloplasty 220
- Appendix 3.1.2.8: Symplicity Catheter/Therapeutic Renal Denervation Procedure 221
- Appendix 3.1.2.9: Laser Circumferential Pulmonary Vein Ablation/Atrial Fibrillation Therapy 222
- Appendix 3.1.2.10: Non-Invasive Cardiac Radiosurgery/CyberHeart 224
- Appendix 3.2: Oncology Market 225
 - Appendix 3.2.1: Diagnostic Technologies 225
 - Appendix 3.2.1.1: Radioactive Trace Biomarker/FLT 225
 - Appendix 3.2.1.2: Vivo Confocal Microscopy / Skin Cancer Diagnosis 227
 - Appendix 3.2.1.3: Lung Cancer/Breath Test 228
 - Appendix 3.2.1.4: Magnetically-Charged Cancer Biomarker/MagArray Technology 229
 - Appendix 3.2.1.5: NIR Tissue Analyzer/Optical Tissue Analyzer 230
 - Appendix 3.2.2: Therapeutic Technologies 231
 - Appendix 3.2.2.1: Acoustic-Enhanced Chemotherapy 231
 - Appendix 3.2.2.2: Electrochemotherapy/Novo – TTF device 232
 - Appendix 3.2.2.3: MRI-Guided Laser Coagulation Therapy (LITT)/AutoLITT 233
 - Appendix 3.2.2.4: MRI-Guided Robotic Radiotherapy/Renaissance System 234
 - Appendix 3.2.2.5: PDT for Solid Tumors/Light Infusion Therapy 236
 - Appendix 3.2.2.6: Prostate Cooling Catheter/UroCool 237
- Appendix 3.3: Gastrointestinal Market 238
 - Appendix 3.3.1: Diagnostic Technologies 238
 - Appendix 3.3.1.1: Urea Breath Test/Breath ID 238
 - Appendix 3.3.1.2: Robotic GI Capsule 239
 - Appendix 3.3.1.3: Minimally Invasive GERD Procedure/EndoFlip 240
 - Appendix 3.3.2: Therapeutic Technologies 242
 - Appendix 3.3.2.1: Non-Invasive Obesity Treatment/LINX Reflux Management 242
- Appendix 3.4: Pulmonology Market 243
 - Appendix 3.4.1: Diagnostic Technologies 243
 - Appendix 3.4.1.1: Electrical Impedance Tomography/EIT Lung Function 243
 - Appendix 3.4.2: Therapeutic Technologies 244
 - Appendix 3.4.2.1: Artificial Lung/Hemolung 244
 - Appendix 3.4.2.2: Endobronchial Valves/Spiration's® IBV 245
- Appendix 3.5: Nursing 247
 - Appendix 3.5.1: Diagnostic Technologies 247
 - Appendix 3.5.1.1: Real-Time Blood Test Glucose, Electrolytes, Amino Acids/MicroEye 247
 - Appendix 3.5.1.2: Drug Metabolism/Breath-Based P450 248
 - Appendix 3.5.2: Therapeutic Technologies 250
 - Appendix 3.5.2.1: Contrast-Induced Nephropathy/RenalGuard Therapy 250
 - Appendix 3.5.2.2: Antimicrobial Coating on Catheters/CeraShield 251
 - Appendix 3.5.2.3: Sepsis Microfilter 252
- Appendix 3.6: Neurology 253
 - Appendix 3.6.1: Diagnostic Technologies 254
 - Appendix 3.6.1.1: Electric Impedance Myography 254
 - Appendix 3.6.1.2: Brain Injury Blood Test/S100B Biomarker 255
 - Appendix 3.6.1.3: Alzheimer's Blood Test/NuroPro, LymPro Test 256
 - Appendix 3.6.1.4: Navigated Brain Stimulation Mapping/eXimia NBS System 257
 - Appendix 3.6.2: Therapeutic Technologies 259
 - Appendix 3.6.2.1: Deep Brain Stimulation/Stroke Therapy 259
 - Appendix 3.6.2.2: Hypoglossal Nerve Stimulation/Sleep Apnea 260
 - Appendix 3.6.2.3: Alzheimer's Therapeutic Drug/PBT2 261
 - Appendix 3.6.2.4: Spinal Cord Nerve Regeneration/Andara™ OFS 262
- Appendix 3.7: Women's Health 263
 - Appendix 3.7.1: Non-Invasive Fetal EKG 264
 - Appendix 3.7.2: Cervical Spectroscopy/Optical Cervical Cancer Detection 265

Appendix 3.7.3: Laser Opto-Acoustic Imaging/Mammography	266
Appendix 3.8: Surgical	267
Appendix 3.8.1: Intraoperative Near-Infrared Guidance Technology	268
Appendix 3.8.2: Acoustic Hemostasis	269
Appendix 3.8.3: Photochemical Bonding	270
Appendix 3.9: Imaging	272
Appendix 3.9.1: Elastography/Advanced Ultrasound	272
Appendix 3.9.2: Computer-Assisted Tortuosity/Tumor Blood Vessel Analysis	273
Appendix 3.9.3: Dynamic Light Scattering/Early Cataract Detection	274
Appendix 4: A Guide for U.S. Exporters of Healthcare Technologies	276
Appendix 4.1: Opportunities in the E.U.	276
Appendix 4.2: U.S. Opportunities in Austria	282
Appendix 4.3: Opportunities in Belgium	283
Appendix 4.4: Opportunities in Bulgaria	284
Appendix 4.5: Opportunities in Czech Republic	286
Appendix 4.6: Opportunities in Denmark	287
Appendix 4.7: Opportunities in Finland	288
Appendix 4.8: Opportunities in France	289
Appendix 4.9: Opportunities in Germany	291
Appendix 4.10: Opportunities in Greece	295
Appendix 4.11: Opportunities in Hungary	298
Appendix 4.12: Opportunities in Ireland	300
Appendix 4.13: Opportunities in Italy	302
Appendix 4.14: Opportunities in Netherlands	304
Appendix 4.15: Opportunities in Norway	305
Appendix 4.16: Opportunities in Poland	306
Appendix 4.17: Opportunities in Romania	308
Appendix 4.18: Opportunities in Slovak Republic	309
Appendix 4.19: Opportunities in Spain	311
Appendix 4.20: Opportunities in Sweden	312
Appendix 4.21: Opportunities in Switzerland	314
Appendix 4.22: Opportunities in Ukraine	315
Appendix 4.23: Opportunities in U.K.	316
Appendix 4.24: Opportunities in Argentina	318
Appendix 4.25: Opportunities in Brazil	319
Appendix 4.26: Opportunities in Dominican Republic	320
Appendix 4.27: Opportunities in Ecuador	322
Appendix 4.28: Opportunities in El Salvador	323
Appendix 4.29: Opportunities in Mexico	324
Appendix 4.30: Opportunities in Panama	325
Appendix 4.31: Opportunities in Israel	326
Appendix 4.32: Opportunities in Saudi Arabia	328
Appendix 4.33: Opportunities in Turkey	331
Appendix 4.35: Opportunities in China	333
Appendix 4.36: Opportunities in India	335
Appendix 4.37: Opportunities in Indonesia	337
Appendix 4.38: Opportunities in Japan	338
Appendix 4.39: Opportunities in Philippines	340
Appendix 4.40: Opportunities in Republic of Korea	341
Appendix 4.41: Opportunities in Singapore	343
Appendix 4.42: Opportunities in Taiwan	344
Appendix 5: A Snapshot of Medical Device Industry, Based on a Survey by Professionals	346
Appendix 5.1: Change in Domestic Sales in 2011	346
Appendix 5.2: Companies Seeking Outside Opportunities for Medical Devices	346
Appendix 5.3: Continued International Expansion of Medical Device Firms in 2011	347
Appendix 5.4: Emerging Markets Targeted by Medical Device Firms in 2012	348

Appendix 5.5: Markets Offering the Best Growth Potential for the Next Five Years 348

Appendix 5.6: The Biggest Challenges in Running a Medical Device Business 349

Appendix 5.7: Prospects for Existing Medical Device Firms in 2012 350

Appendix 5.8: Medical Device Firm's Outlook on Overall Business Environment in 2012 351

Appendix 6: Medtech Mergers and Acquisitions, 2011 352

Appendix 6.1: J & J's Acquisition of Synthes 352

Appendix 6.2: Stryker's Strike 352

Appendix 6.3: The Battle Won by Danaher 353

Appendix 6.4: Major Acquisition for Private Equity Firm 353

Appendix 6.5: Thermo Fisher's Hook on Diagnostics Companies 353

Appendix 6.6: Other Diagnostics Transactions 353

Appendix 6.7: Pelvic Health Transactions 354

Appendix 6.8: Diversification Move by Dentsply 354

Appendix 6.9: Genting's Foray into Cardiovascular Sector 355

Appendix 6.10: Medtronic's Hyperactive Year 355

Appendix 6.11: Acquisition of U.S. Companies by Japanese 355

Appendix 6.12: Boston Scientific's Acquisition Trail 356

Appendix 6.13: Future Outlook 356

Appendix 7: Hospital Acquired Infections in Europe 358

Appendix 7.1: Urinary Tract Infections 358

Appendix 7.2: Respiratory Infections 359

Appendix 7.3: Blood Stream Infections 359

Appendix 7.4: Surgical Site Infections 360

Appendix 7.5: Other Infections 360

Appendix 7.6: An Overview of Hospital-Acquired Infections (HAI) 361

Appendix 7.7: Prevalence of HAI in Europe 361

Appendix 7.8: Microorganisms Isolated from HAIs 362

Appendix 7.9: Hospitals and Infections 362

Appendix 7.9.1: HAIs Based on Wards 363

Appendix 7.9.2: HAIs from Intensive Care Units 363

Appendix 7.10: An Overview of Urinary Tract Infections 363

Appendix 7.10.1: Catheter Associated Urinary Tract Infections (CAUTI) 365

Appendix 7.10.2: HAIs UTI Population in Europe 365

Appendix 7.11: Hospital-Acquired Pneumonia Infections 366

Appendix 7.11.1: Hospital-Acquired Pneumonia Infection in ICUs 367

Appendix 7.12: Surgical Site Infections 368

Appendix 7.12.1: SSI in Orthopedic Surgery 368

Appendix 7.13: Bloodstream Infections 369

Appendix 7.13.1: Catheter-Related Bloodstream Infections 369

Appendix 7.14: Antimicrobial Resistance 370

Appendix 7.15: HAIs in France 372

Appendix 7.16: HAIs in Germany 373

Appendix 7.17: HAIs in Italy 374

Appendix 7.18: HAIs in Spain 374

Appendix 7.19: HAIs in U.K. 375

Appendix 8: IV Catheter Needlestick Prevention in Europe 377

Appendix 8.1: Occurrence of Needlestick Injuries 378

Appendix 8.2: Transmissible Diseases 378

Appendix 8.2.1: Hepatitis B Virus (HBV) Infection 379

Appendix 8.2.2: Hepatitis C Virus Infection (HCV) 380

Appendix 8.2.3: HIV/AIDS 381

Appendix 8.3: Safety Devices in Catheters 382

INDEX OF FIGURES

- Figure 2.1: Insertion of Foley Catheters into Male and Female Urinary Tracts 39
- Figure 3.1: Projection for All Cardiovascular Disease Prevalence (%) in the U.S., 2010-2030 41
- Figure 3.2: Projected Direct Medical Cost of All Cardiovascular Diseases in the U.S., 2010-2030 41
- Figure 3.3: Projections for the Prevalence of Hypertension in the U.S., 2010-2030 42
- Figure 3.4: Projected Direct Medical Cost of Hypertension in the U.S., 2010-2030 42
- Figure 3.5: Projections for the Prevalence of Coronary Heart Disease in the U.S., 2010-2030 43
- Figure 3.6: Projected Direct Medical Cost of Coronary Heart Disease in the U.S., 2010-2030 43
- Figure 3.7: Projections for the Prevalence of Heart Failure in the U.S., 2010-2030 44
- Figure 3.8: Projected Direct Medical Cost of Heart Failure in the U.S., 2010-2030 44
- Figure 3.9: Projections for the Prevalence of Stroke in the U.S., 2010-2030 45
- Figure 3.10: Projected Direct Medical Cost of Stroke in the U.S., 2010-2030 45
- Figure 3.11: Ischemic Heart Disease, Mortality Rates in Selected OECD Countries, 2009 46
- Figure 3.12: Stroke Mortality Rates in Selected OECD Countries, 2009 47
- Figure 3.13: Total Worldwide Cardiovascular Devices Market, 2011-2018 48
- Figure 3.14: Leaders in Cardiovascular Devices Market 49
- Figure 3.15: Estimated New Cancer Cases in the U.S. for Select Sites, 2011 50
- Figure 3.16: All Cancers Mortality Rates in Selected OECD Countries, 2009 53
- Figure 3.17: Lung Cancer Mortality Rates in Selected OECD Countries, 2009 54
- Figure 3.18: Breast Cancer Mortality Rates in Selected OECD Countries, 2009 55
- Figure 3.19: Prostate Cancer Mortality in Males in Selected OECD Countries, 2009 56
- Figure 3.20: Global Oncology Market, 2011-2018 57
- Figure 3.21: Prevalence of Patients Undergoing Dialysis in OECD Countries, 1990 and 2009 58
- Figure 3.22: Prevalence of Patients Living with a Functioning Kidney Transplant, 1990 and 2009 59
- Figure 3.23: Worldwide Dialysis Market, 2011-2018 60
- Figure 3.24: Global Number of Dialysis Patients, 2011 61
- Figure 3.25: Number of U.S. Dialysis Patients, 2011-2018 61
- Figure 3.26: U.S. Dialysis Market, 2011-2018 62
- Figure 3.27: U.S. Dialysis Procedures by Segment, 2011 63
- Figure 4.1: Worldwide market for Medical Devices, 2011-2018 64
- Figure 4.2: Medical Device Market in Americas, 2011-2018 65
- Figure 4.3: Medical Device Market in Western Europe, 2011-2018 66
- Figure 4.4: Medical Device Market in Central and Eastern Europe, 2011-2018 66
- Figure 4.5: Medical Device Market in Asia/Pacific, 2011-2012 67
- Figure 4.6: Medical Device Market in Middle East/Africa, 2011-2018 68
- Figure 4.7: Combined Chinese and Indian Market for Medical Devices, 2011-2018 68
- Figure 5.1: Global Catheter Market Sales Segmentation 70
- Figure 5.2: Global Catheter Market, 2011-2018 71
- Figure 5.3: Market for Catheters in Americas, 2011-2018 71
- Figure 5.4: Catheter Market in Europe, Middle East, Russia and Africa, 2011-2018 72
- Figure 5.5: Catheter Market in Asia/Pacific, 2011-2018 73
- Figure 5.6: Catheter Market in Japan, 2011-2018 73
- Figure 5.7: Global Catheter Market by Region, 2011 74
- Figure 5.8: Global Catheter Market by Segmentation in 2014 75
- Figure 5.9: Global Market for Cardiovascular Catheters, 2011-2018 76
- Figure 5.10: Global Diagnostic Cardiac Catheter Market by Type, 2011 77
- Figure 5.11: Global Market for Balloon Catheters, 2011-2018 77
- Figure 5.12: Estimated Addressable U.S. Market for Drug-Coated Balloon Catheters 78
- Figure 5.13: U.S. Market for Drug Coated Balloon Catheters in Peripheral Applications 79
- Figure 5.14: Global Market for Electrophysiology Ablation Catheters, 2011-2018 79
- Figure 5.15: North American Market for Electrophysiology Ablation Catheters, 2011-2018 80
- Figure 5.16: European Market for Electrophysiology Ablation Catheters, 2011-2018 81
- Figure 5.17: Asia/Pacific Market for Electrophysiology Ablation Catheters, 2011-2018 81
- Figure 5.18: Global Single Use Device (SUD) Cardiac Catheter Market, 2011-2018 82
- Figure 5.19: Global Market for SUD Cardiac Catheters Used in Conventional Diagnostics, 2011-2018 83

- Figure 5.20: Global Market for SUD Cardiac Catheters Used in Standard Ablation, 2011-2018 83
- Figure 5.21: Global Market for SUD Cardiac Catheters Used in Advanced Diagnostics, 2011-2018 84
- Figure 5.22: Global Market for SUD Cardiac Catheters Used in Irrigated Ablation, 2011-2018 85
- Figure 5.23: Global Market for Urological Catheters, 2011-2018 85
- Figure 5.24: Manufacturers with Largest Number of FDA-Approved Catheters 86
- Figure 5.25: U.S. Urology Device Market by Segment, 2011 87
- Figure 5.26: U.S. Intermittent Catheter Market, 2011-2018 88
- Figure 5.27: Market Leaders in Intermittent Catheters 88
- Figure 5.28: Market Leaders in Foley Catheters 89
- Figure 5.29: U.S. Market Share of Urinary Incontinence Products by Type 89
- Figure 5.30: U.S. Urinary Incontinence Market by Sub-Segment, 2011 90
- Figure 5.31: Market Leaders in Male External Catheters 90
- Figure 5.32: Global Market for Central Venous Catheters, 2011-2018 91
- Figure 5.53: CVC Global Market by Region/Country 92
- Figure 5.54: Leaders in the Global Central Venous Catheter Market 92
- Figure 5.55: U.S. Market Leaders in Implantable Catheter Ports, 2010 93
- Figure 6.1: Relative Share of Ablation Technologies Market by Clinical Specialty, 2010 95
- Figure 6.2: Global Ablation Devices Market by Device Type, 2011 95
- Figure 6.3: Global Market for Electrical Ablation Devices, 2011-2018 96
- Figure 6.4: Global Market for Radiation Ablation Devices, 2011-2018 97
- Figure 6.5: Global Market for Light-Based Ablation Devices, 2011-2018 98
- Figure 6.6: Global Market for Radiofrequency Ablation Devices, 2011-2018 99
- Figure 6.7: Market Leaders in RF Ablation Devices, 2011 99
- Figure 6.8: Global Market for Ultrasound Ablation Devices, 2011-2018 100
- Figure 6.9: Global Market for Cryotherapy Ablation Devices, 2011-2018 100
- Figure 6.10: Global Market for Thermal Ablation Devices, 2011-2018 101
- Figure 6.11: Global Market for Microwave Ablation Devices, 2011-2018 102
- Figure 6.12: Global Market for Hydromechanical Ablation Devices, 2011-2018 102
- Figure 6.13: U.S. Market for Tissue Ablation Devices, 2011-2018 103
- Figure 6.14: U.S. Market for Cryoablation Devices, 2011-2018 104
- Figure 6.15: U.S. Market for Hydromechanical Ablation Devices, 2011-2018 104
- Figure 6.16: U.S. Market for Ultrasound Ablation Devices, 2011-2018 105
- Figure 6.17: U.S. Market for Radiofrequency Ablation Devices, 2011-2018 106
- Figure 6.18: Asia/Pacific Market for Ablation Devices, 2011-2018 106
- Figure 6.19: Growth in Japanese Market for Ablation Technologies, 2011-2018 107
- Figure 6.20: Growth in Chinese Market for Ablation Technologies, 2011-2018 108
- Figure 6.21: Growth in Australian Market for Ablation Technologies, 2011-2018 108
- Figure 6.22: Growth in Indian Market for Ablation Technologies, 2011-2018 109
- Figure 6.23: Relative Share of Ablation Technologies Market by Clinical Specialty, 2010 110
- Figure 6.24: Cancer Ablation Market Segmentation, 2011 110
- Figure 6.25: Global Ablation Technologies Market by Modality, 2011 111
- Table 9.1 IV Catheters from BD 150
- Figure A.2.1: Number of Minimally-Invasive Surgeries Worldwide 201
- Figure A2.2: Market for Minimally-Invasive Medical Technologies by Region/Country, 2009-2014 202
- Figure A2.3: Market Share of Minimally-Invasive Medical Technologies by Device Type 202
- Figure A2.4: Profound Medical's Energy Wand Emitting Ultrasound in Two Different Wavelengths 206
- Figure A2.5: Coil RFA Ablation Technology for Treating Solid Tumors 207
- Figure A4.1: French Medical Device Market Size, 2009-2011 290
- Figure A4.2: German Medical Market, 2009-2011 292
- Figure A4.3: Size of Turkey's Medical Device Market, 2010-2012 332
- Figure A4.4: Medical Device Market in Republic of Korea, 2008-2010 341
- Figure A5.1: Change in Domestic Sales by Medical Device Companies in 2011 346
- Figure A5.2: Change in International Sales of Medical Devices in 2011 347
- Figure A5.3: Continued International Expansion of Medical Device Firms in 2011 347
- Figure A5.4: Emerging Markets Targeted by Medical Device Firms in 2012 348
- Figure A5.5: Markets Offering the Best Growth Potential from 2012-2017 349

Figure A5.6: Biggest Challenges in Running a Medical Device Business 350
 Figure A5.7: Prospects for Existing Medical Device Firms in 2012 350
 Figure A5.8: Medical Device Firm's Outlook on Overall Business Environment in 2012 351
 Figure A7.1: Hospital-Acquired Infections: Percent Split by Type in Europe 362
 Figure A7.2: HAIs of Urinary Tract Infections (UTI) Percent by Type 364
 Figure A7.3: HAIs of Urinary Tract Percent Split by Pathogens 364
 Figure A7.4: Population of HIS UTI Population in Europe by Country 366
 Figure A7.5: Six Most Common Pathogens of Pneumonia Infection in ICUs 367
 Figure A7.6: Incidence of SSI by Type of Orthopedic Surgery 368
 Figure A7.7: Bloodstream Infections by Site of Origin 369
 Figure A7.8: HAIs in France by Type 372
 Figure A7.9: HAIs in Germany by Type 373
 Figure A7.10: HAIs in Spain by Type of Pathogen 374
 Figure A7.11: HAIs in the U.K. by Type 375
 Figure A8.1: Frequency of Needlestick Injuries in Europe and the U.S. 377
 Figure A8.2: Occurrence of Needlestick Injuries 378
 Figure A8.3: The Three Dangerous Infections through Needlestick Injuries 379
 Figure A8.4: Percent Population of Chronic HBV Infected People by Region 380
 Figure A8.5: The Prevalence Rate of Chronic Hepatitis C Virus in Europe 380
 Figure A8.6: The Prevalence Rate of Chronic Hepatitis C Virus in Europe 381
 Figure A8.7: People Living with HIV by Region 382

INDEX OF TABLES

Table 7.1: Medicare Fee Schedule for Common Cath Procedure Codes in the State of Washington 112
 Table 7.2: Payer Mix for Cath Procedures 113
 Table 7.3: Projected Revenue in Free Standing Cath Lab 114
 Table 7.4: Suggested Minimal Room Sizes in a Cardiac Cath Suite 115
 Table 7.5: Medicare Reimbursement 2009: Hospital O.P Department vs. Free Standing Cath Lab 117
 Table 7.6: Revenue Projections Based on 50% Practice 118
 Table 8.1: Codes and Payments for Catheter Procedures, 2012 121
 Table A4.1: The Top Three Countries in the Export and Import of Medical Devices into China, 2010 334
 Table A6.1: Medtech Merger and Acquisition, 2011 357
 Table A7.1: Pathogens Causing CAUTI Ranked in Order 365
 Table A7.2: Classification of Pathogens Based on the Onset of Pneumonia 367
 Table A7.3: MRSA Incidence per 100,000 Patient Days in Europe 370
 Table A7.4: List of Antibiotic Resistant Pathogens 370
 Table A7.5: Economic Burden of Infections Due to Antibiotic-Resistant Bacteria 371

1. Introduction

Catheters are used in a number of processes, e.g., cardiovascular, urological, intravenous, oximetry, thermodilution, suction and wound drainage processes that involve the administration or drainage of fluids from the body. The global market for catheters is vibrant and continually evolving with significant investments to improve the capabilities of existing catheters, improve safety features and identify new medical applications. The growing number of aged people undergoing diagnostic and therapeutic procedures is driving increases in catheter sales. Government regulations also play a key role, mainly in the urological catheter segment, as regulations attempt to promote fewer infections among hospitalized patients through more frequent use of catheterization. This TriMark Publications report provides a detailed analysis of the global market for catheters, including central venous catheters (CVCs), peripheral venous catheters (PVC), midline catheters (MC), hemodialysis catheters, pulmonary artery catheters, peripheral artery catheters and umbilical catheters. The study also analyzes almost all of the companies known to be marketing, manufacturing or developing catheter products in the U.S. and worldwide. Detailed tables, charts and figures are included with projected sales data by geographic region for the Americas, EMRA (Europe, the Middle East, Russia, Africa) and Asia-Pacific regions.

1.1 Scope of this Report

The report provides a thorough overview of the applications of catheters in different clinical procedures; the different types of catheters used in cardiovascular, urological, neurovascular and intravenous applications. The report also briefly discusses about the merits and demerits of the three raw materials: silicones, polyvinyl chloride and latex used in the manufacture of catheters. A section of the report deals briefly with the common disease conditions that fuel the growth of catheter market. As the catheters are medical devices, the study also discusses the overall medical device market in the U.S., Europe and Asia/Pacific. The major section of this analysis covers in detail the market for different catheter types, the market leading vendors and market trends in different geographical regions for catheters. The reader should consult other TriMark Publications reports at <http://www.trimarkpublications.com> for details on individual market segments related to medical devices and supplies, including TriMark's *Disposable Syringe Markets* and *Disposable Medical Supplies Markets* reports.

1.2 Methodology

The author of this report is a retired college professor with more than 30 years of experience in teaching biochemistry, biochemical pharmacology, biotechnology and molecular biology. He also has four years of experience in editing market research reports on healthcare topics. Company-specific information for this report has been obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additionally, sources of information include the non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities like the U.S. Department of Health and Human Services (HHS) and U.S. federal agencies such as the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that we publish annually. We extract relevant data and analytics from TriMark's research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

TriMark Publications Report, Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.
- Formulating a study outline with the assigned writer, including important items, as follows:
 - Market and product segment grouping, and evaluating their relative significance.
 - Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
 - End-user research to evaluate analytical significance in market estimation.
 - Supply chain research and analysis to identify any factors affecting the market.
 - New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets.
- Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of expert panel partners from the industry being analyzed.

1.3 Executive Summary

The global catheter market has been valued at \$██████████ in ██████████. The key growth drivers are aging population in both developed and emerging markets, product innovations and patient's choice for minimally invasive procedures. Just as in other medical devices, U.S. is the largest market for catheters and the U.S. medical device companies produce nearly ██████████% to ██████████% of catheter products that are being used worldwide. Among the different types of catheters, cardiovascular catheters account for about ██████████% of the global catheter market. The other catheters available in the global market are urological catheters, intravenous catheters, oximetry catheters, thermodilution catheters, suction catheters and wound drainage catheters. The specialty catheters, intravenous catheters and urological catheters have a share of ██████████%, ██████████% and ██████████% respectively. In ██████████, North America accounted for approximately ██████████% of the global market while Europe represented ██████████% of the market. Asia-Pacific is the fastest growing region with a CAGR of ██████████%. Americas as a whole accounted for a market of \$██████████ in ██████████ and this is assumed to reach \$██████████ in ██████████. The second largest market includes the EMRA countries (Europe, Middle East, Russia and

Africa). The aging population in Europe demands all types of surgical interventions, particularly cardiovascular, orthopedic, urological and dermatological procedures and consequently account for the huge consumption in this region. In [REDACTED], the countries in the EMRA region had a market for catheters valued at \$ [REDACTED] with a potential to reach \$ [REDACTED] in [REDACTED].

Though smaller than other regions, the Asia/Pacific market is the fastest growing one with a CAGR of [REDACTED]%. The market is characterized by the demand for low-cost catheters particularly in the urological sector. Dialysis catheters have relatively the largest market and the region has been experiencing a shift from hemodialysis to peritoneal catheters. The increasing incidence of coronary artery disease has contributed much to a huge demand for percutaneous transluminal coronary angioplasty (PTCA). The Asia/Pacific market for catheters in [REDACTED] was valued at \$ [REDACTED] and it has the potential to reach \$ [REDACTED] in [REDACTED]. The Japanese live longer than others, although they spend only half as much as on healthcare as Americans do, as they visit doctors more frequently. Use of intravascular ultrasound catheters is high in Japan as the physicians are interested in accurate lesion sizing. The Japanese catheter market size was for about \$ [REDACTED] in [REDACTED] and it is predicted to reach \$ [REDACTED] in [REDACTED].

Age, obesity, physical inactivity and diabetes are the major contributory factors for cardiovascular diseases. The global cardiovascular catheter market is successfully being promoted by newer and novel innovations in catheters that ensure improved maneuverability and insertion capabilities. The U.S. is the largest market for cardiovascular catheters with a share of about [REDACTED]%. In the U.S. EP ablation catheter market is the fastest growing one with a CAGR of [REDACTED]%. RF ablation catheters are gaining prominence for managing atrial fibrillation. The global cardiovascular catheter market was worth about \$ [REDACTED] and it has been predicted to reach \$ [REDACTED] in [REDACTED].

The various types of urological catheters available in the global market include urological catheters, urethral catheters, balloon retention type catheters, straight catheters, upper urinary tract catheters etc. The urological catheters category includes [REDACTED] approved products from [REDACTED] different companies. Increasing incidence of urological problems in the global aging population is understood to be the market driver. From the value of \$ [REDACTED] in [REDACTED], this market has the potential to reach \$ [REDACTED] in [REDACTED]. The total market value for the different kinds of urological products was about \$ [REDACTED] in [REDACTED] and the urinary incontinence products had the largest share of about \$ [REDACTED].

The past few decades have witnessed an increased growth of central venous access devices. Nearly about [REDACTED] central venous catheters per year are used in the U.S. We estimate that the market for CVC was worth about \$ [REDACTED] in [REDACTED] and expect this to grow and reach \$ [REDACTED] in [REDACTED]. The U.S., Europe and Japan accounted for nearly [REDACTED]% of the global central intravenous catheter market, with the U.S. alone accounting for [REDACTED]%.

Tissue ablation devices are used to produce a therapeutic affect on tissue, by its destruction, excision, sealing or simply the formation of a clinically beneficial lesion. The tissue ablation market has a vast potential for growth and the application of these devices encompass the entire clinical range in medical and surgical technology. The technologies that include ablation embrace nine distinct categories: electrical, radiation, light, radiofrequency, ultrasound, cryotherapy, thermal (other than cryotherapy), microwave and hydromechanical. Together all these devices had a market for about \$ [REDACTED] in [REDACTED].